KUBOTA PHARMACEUTICAL HOLDINGS CO LTD
Healthcare · Pharmaceutical Preparations · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY16 | FY15 | FY14 | FY13 | FY12 | |
|---|---|---|---|---|---|
| Revenue | $3.8M | $7.2M | $35.4M | $52.9M | $46.4M |
| Operating income | −$36.0M | −$26.6M | −$188,000 | $7.0M | $7.0M |
| Net income | −$12.6M | −$3.9M | −$2.0M | $4.3M | $4.2M |
| Total assets | $147.4M | $175.9M | $197.0M | $54.0M | — |
| Total liabilities | — | — | — | — | — |
| Equity | $141.8M | $166.4M | $184.4M | $31.1M | $25.6M |
| EPS (diluted) | $-0.34 | $-0.11 | $-0.06 | $0.09 | $0.09 |
| Shares out. | 37.6M | 35.8M | 35.8M | 12.0M | 12.2M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2016- Operating margin
- −958.4%
- Net margin
- −335.2%
- Return on equity
- −8.9%
- Return on assets
- −8.5%
- Return on capital (ROCE)
- −25.2%
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $3.77
- Revenue growth (YoY)
- −47.9%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2016- Accruals / assets
- 10.1%high accruals
- Piotroski F-Score
- 1/8weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 5 warning● 0 good- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- High accruals — earnings-quality risk
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Other material eventJul 26, 2017
- Shareholder vote · Other material eventMay 26, 2017
- Entered a material agreement · New financial obligationMay 25, 2017
- Results of operationsMay 10, 2017
- Director / officer changeFeb 24, 2017
- Regulation FD disclosureFeb 21, 2017
- Results of operationsFeb 14, 2017
- Entered a material agreementJan 18, 2017
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- EFFECTDec 11, 2017
- S-8 POSPOST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8Dec 7, 2017
- POS AMPOST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-3Dec 7, 2017
- 15F-12G/ADec 7, 2017
- 15F-12GDec 6, 2017
- 6-KNov 9, 2017
- 6-KAug 8, 2017
- 8-KJul 26, 2017
- 4FORM 4Jul 18, 2017
- 4FORM 4Jul 5, 2017
- 4FORM 4Jul 5, 2017
- 4FORM 4Jun 20, 2017
- 4FORM 4Jun 2, 2017
- 4FORM 4Jun 2, 2017
- 8-KMay 26, 2017